Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CStone Starts China Bridging Trial of Leukemia Treatment in China

publication date: Nov 22, 2019

CStone Pharma has dosed the first patient in a China Phase I bridging trial of ivosidenib (Tibsovo®) in patients with acute myeloid leukemia. Developed by Agios, ivosidenib was approved in the US in July 2018 to treat adult patients with relapsed/refractory AML with a susceptible IDH1 mutation, using a biomarker to test for the mutation. Earlier this year, CStone submitted an NDA for ivosidenib in Taiwan. The new China trial will assess the efficacy, safety and pharmacokinetics of ivosidenib in patients with IDH1 mutant R/R AML. More details....

Stock Symbols: (HK: 2616) (NSDQ: AGIO)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.